Home » Newsletters » BioWorld Science

BioWorld Science

Sep. 14, 1999

View Archived Issues

Prophylaxis of venous thromboembolism with enoxaparin assessed in hospitalized patients

Maxamine treatment leads to tumor regression in preclinical model of prostate cancer

Novel photoprobe for locating sites of action of general anesthetics

MS-275: new benzamide inhibitor of histone deacetylase selected as development candidate

Nonimmunosuppressive cytokine synthesis inhibitor effective in murine model of septic shock

Pharmacokinetics, metabolism of E-5842 studied in animals

Alinastine: pharmacological properties indicate benefit in seasonal allergic rhinoconjunctivitis

CCK/gastrin receptor ligands developed at James Black Foundation

Cell Pathways continues to investigate apoptosis-promoting compounds for neoplastic diseases

Korean scientists present new compounds for depression and other CNS disorders

Endothelin antagonists described by BMS for hypertension, etc.

Isis and Abbott initiate collaboration for antisense drugs

Newly patented naphthyridines antagonize IL-4 and enhance G-CSF production

Kosan achieves research milestone in collaboration with PRI

Novel antiparasitic agents designed at Johns Hopkins

Potential benefit of riluzole in epilepsy investigated in animal model

Maxalt approved in Canada for migraine therapy

Ciba Vision and QLT initiate T-IND clinical program for Visudyne therapy

23rd IEC news: pharmacokinetics of remacemide in renal or hepatic insufficiency

XTL and Lilly to collaborate on HCV therapy research

Transgene commences phase I trial for treatment of cervical cancer

Alteon and Taisho enter option agreement for AGE crosslink breaker

Chiron seeks U.K. approval for meningitis vaccine

Alza stockholders to vote on merger with Abbott next week

Potential new antidepressant exhibits biphasic effects on 5-HT uptake and 5-HT1A receptors

The Cystic Fibrosis Foundation funds drug discovery program at Aurora

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for Feb. 3, 2025.
Today's news in brief
Briefs
BioWorld MedTech briefs for Jan. 30, 2026.
Centessa’s CNT-9982 shows promise for MDD
BioWorld Science
Orexin OX2 receptor agonists have demonstrated the ability to enhance wakefulness in rodent models, as well as in nonhuman primates and patients with narcolepsy...
First-in-class ADC targeting DEM-TXX shows high preclinical efficacy
BioWorld Science
Researchers at DEM Biopharma Inc. reported preclinical findings demonstrating the efficacy of DEM-301, a bifunctional antibody-drug conjugate (ADC) engineered to...
5-HT2R allosteric ligands attenuate cocaine use and seeking behavior
BioWorld Science
Serotonergic G-protein-coupled receptors (GPCRs), including the 5-HT2A receptor (5-HT2AR) and 5-HT2CR, are key regulators of cortical signaling pathways and...